Table 1.
Patients | Age | HPV 16 before vaccine | HPV 16 prior to LEEP | Initial histology | End histology after LEEP | Clinical status | Immune response |
---|---|---|---|---|---|---|---|
01 | 43 | + | + | CIN II | Koilocytosis | CR | + |
02 | 38 | + | + | CIN III | CIN III | SD | + |
03 | 24 | + | + | CIN III | CIN II | PR | + |
04 | 25 | + | − | CIN II | Koilocytosis | CR | + |
05 | 26 | + | − | CIN III | Koilocytosis | CR | + |
06 | 25 | + | − | CIN III | Negative | CR | + |
07 | 25 | + | + | CIN III | CIN III | SD | + |
Note: All patients were positive for HLA-A2.
Initial histology was by cervical biopsy prior to the study. End histology was by LEEP at termination of the study (90 days after the first vaccine administration).
Abbreviations
CIN II-III: cervical intraepithelial neoplasia, grade II or III.
CR: complete response; PR: partial response; SD: stable disease.